Last reviewed · How we verify
NCT04985526: PLE_microbio
Skin Microbiome and Polymorphic Light Eruption
NA trial testing Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) in Polymorphic Light Eruption in 30 participants. Status unknown.
30 June 2022
Quick facts
| Lead sponsor | Medical University of Graz |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 30 |
| Start date | 7 May 2021 |
| Primary completion | 30 June 2022 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)
Conditions studied
- Polymorphic Light Eruption — all drugs for Polymorphic Light Eruption →
Sponsor
Medical University of Graz
Who can join
Adults 18 to 65, any sex, with Polymorphic Light Eruption. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Polymorphic light eruption (PLE) is the most common form among UV-inducible disorders with a prevalence of approximately 11-21% worldwide and a clear predisposition of women. Usually, within several hours after an intense UV exposure, most likely in spring or early summer, the formation of itchy skin lesions particularly at the upper arms and V-neck and neck is distinctive for PLE. It has been suggested that the development of a potential photo-induced antigen may initiate a delayed-type hypersensitivity reaction in PLE (causing the skin rash) and the microbiota of the skin may be involved. We thus hypothesized that eliminating the microbiota of the skin by disinfection may affect the formation of PLE. The concept of this study covers a combined interindividual and intraindividual half-body comparison of the skin reactions of disinfected and contralateral non-disinfected areas upon UV exposure in PLE patients and healthy subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04985526
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Medical University of Graz trials
Trials by the same sponsor.
- NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
- NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
- NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
- NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
- NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04985526 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
- Last refreshed: 2 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04985526.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing